1. D. T. Monaghan, R. J. Bridges, and C. W. Cotman, “The excitatory amino acid receptors: Their classes, pharmacology, and distinct properties in the function of the central nervous system,” Annu. Rev. Pharmacol. Toxicol., 29, 365–402 (1989).
2. S. D. Iversen, “Interaction between excitatory amino acids and dopamine systems in the forebrain: Implications for schizophrenia and Parkinson disease,” Behav. Pharmacol., 6, 478–491 (1995).
3. J. W. Olney and N. B. Farber, “NMDA-antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying of schizophrenia,” Neuropsychopharmacology, 13, 335–345 (1995).
4. B. S. Meldrum, “The role of glutamate in epilepsy and other CNS disorders,” Neurology, 44, S14–S23 (1994).
5. I. A. Paul, G. Nowak, R. T. Layer, et al., “Adaptation of the N-methyl-D-aspart te receptor complex following chronic antidepressant treatments,” J. Pharmacol. Exp. Ther., 269, 95–102 (1994).